Last Updated: November 15, 2026

Travere Company Profile

« Back to Dashboard


What is the competitive landscape for TRAVERE

TRAVERE has one approved drug.

There are three US patents protecting TRAVERE drugs.

Summary for Travere
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Travere

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Travere FILSPARI sparsentan TABLET;ORAL 216403-001 Feb 17, 2023 RX Yes No 9,662,312 ⤷  Start Trial ⤷  Start Trial
Travere FILSPARI sparsentan TABLET;ORAL 216403-002 Feb 17, 2023 RX Yes Yes 9,662,312 ⤷  Start Trial ⤷  Start Trial
Travere FILSPARI sparsentan TABLET;ORAL 216403-002 Feb 17, 2023 RX Yes Yes 9,993,461 ⤷  Start Trial ⤷  Start Trial
Travere FILSPARI sparsentan TABLET;ORAL 216403-001 Feb 17, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial
Travere FILSPARI sparsentan TABLET;ORAL 216403-001 Feb 17, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial
Travere FILSPARI sparsentan TABLET;ORAL 216403-002 Feb 17, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Travere FILSPARI sparsentan TABLET;ORAL 216403-002 Feb 17, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Travere Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3222277 PA2024527 Lithuania ⤷  Start Trial PRODUCT NAME: SPARSENTANAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1788 20240419
3222277 C202430038 Spain ⤷  Start Trial PRODUCT NAME: ESPARSENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1788; DATE OF AUTHORISATION: 20240419; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1788; DATE OF FIRST AUTHORISATION IN EEA: 20240419
3222277 122024000053 Germany ⤷  Start Trial PRODUCT NAME: SPARSENTAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; AUTHORISATION NO/DATE: EU/1/23/1788 20240419
3222277 C20240031 Finland ⤷  Start Trial
3222277 24C1038 France ⤷  Start Trial PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1788 20240423
3222277 LUC00357 Luxembourg ⤷  Start Trial PRODUCT NAME: SPARSENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1788 20240423
3222277 2024C/537 Belgium ⤷  Start Trial PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1788 20240423
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.